Kite Pharma Inc (KITE)

179.79
0.02 0.01
Prev Close 179.81
Open 179.82
Day Low/High 179.55 / 179.95
52 Wk Low/High 39.82 / 179.95
Volume 3.76M
Avg Volume 2.18M
Exchange
Shares Outstanding 57.36M
Market Cap 10.31B
EPS -5.50
Div & Yield N.A. (N.A)

Latest News

Which Hot Biotech Name Will Be Acquired Next?

Which Hot Biotech Name Will Be Acquired Next?

Your burning biotech questions answered in our latest mailbag.

Bret Jensen's Biotech Mailbag

Bret Jensen's Biotech Mailbag

We'll answer two of the common questions we have received so far in March.

These 2 Biotech Stocks Still Have Upside

These 2 Biotech Stocks Still Have Upside

The biotech sector has seen a big rally, but there are still opportunities.

2 Biotech Acquisition Candidates That Could Be Next in M&A Crosshairs

2 Biotech Acquisition Candidates That Could Be Next in M&A Crosshairs

Outside of oncology, the rare disease area is a good target for M&A in 2018.

Circle These Biotech Acquisition Candidates

Circle These Biotech Acquisition Candidates

Outside of oncology, the rare disease area is a good target for M&A in 2018.

10 Biotech Stocks Investors Should Put on Their Shopping List for 2018

10 Biotech Stocks Investors Should Put on Their Shopping List for 2018

Biotech M&A activity will pick up markedly in 2018, and these companies are likely to be the most active in that space.

10 Biotech Stocks to Watch in 2018

10 Biotech Stocks to Watch in 2018

There are a variety of players that should be active in the M&A space next year.

Gilead Has Trouble Written All Over It

Gilead Has Trouble Written All Over It

Getting back into an uptrend will be a challenge for GILD.

Chart of the Day: Gilead

Getting back into an uptrend will be a challenge for GILD.

3 Biotech Stalwarts Just Can't Bio a Break

3 Biotech Stalwarts Just Can't Bio a Break

The stocks of Amgen, Celgene and Gilead Sciences all took hits after posting quarterly results.

Why Is Flexion Falling, and Other Questions

Why Is Flexion Falling, and Other Questions

The first part of Flexion's decline can be attributed to some profit taking.

Gilead Sciences Completes Acquisition Of Kite Pharma, Inc.

Gilead Sciences Completes Acquisition Of Kite Pharma, Inc.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction for Dodgers Merger Sub, Inc.

Gilead Sciences Completes Tender Offer For All Outstanding Shares Of Kite Pharma, Inc.

Gilead Sciences Completes Tender Offer For All Outstanding Shares Of Kite Pharma, Inc.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the successful completion of the tender offer by its wholly-owned subsidiary, Dodgers Merger Sub, Inc.

Gilead Sciences And Kite Pharma Announce Expiration Of Hart-Scott-Rodino Waiting Period

Gilead Sciences And Kite Pharma Announce Expiration Of Hart-Scott-Rodino Waiting Period

Gilead Sciences, Inc. (Nasdaq: GILD) and Kite Pharma, Inc.

Juno, bluebird In Focus as Targets Following Gilead-Kite Aquisition

Juno, bluebird In Focus as Targets Following Gilead-Kite Aquisition

More Immunotherapy Buyouts Likely After Kite Sale

Faster Rebuild After Harvey; Micron Tech Breakout Would Be a Win: Best of Cramer

Faster Rebuild After Harvey; Micron Tech Breakout Would Be a Win: Best of Cramer

Cramer explains why the rebuilding of Houston will be faster than the rebuilding of New Orleans after Katrina and considers how a Micron Tech breakout would be a win for technology stocks.

Getting Bullish on Gilead

Getting Bullish on Gilead

I'm setting up a risk reversal to either buy the stock lower or participate in the upside.

How A Girl from India Came to Rule JPM's North America M&A Group

How A Girl from India Came to Rule JPM's North America M&A Group

Getting M&A insight from JPM's Anu Aiyengar is like winning the lotto.

Stay Focused on the Green Lights: Cramer's 'Mad Money' Recap (Wed 8/30/17)

Stay Focused on the Green Lights: Cramer's 'Mad Money' Recap (Wed 8/30/17)

From political signals to the rebuilding and recovery efforts in Texas, Jim Cramer says investors should pay attention to what's supporting stocks.

Cramer: There Should Be More Takeovers Where These Came From

Cramer: There Should Be More Takeovers Where These Came From

Buying's good for the acquirers, which should give other companies ideas.

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors Of An Investigation Concerning Whether The Sale Of Kite Pharma, Inc. To Gilead Sciences, Inc. Is Fair To Shareholders

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors Of An Investigation Concerning Whether The Sale Of Kite Pharma, Inc. To Gilead Sciences, Inc. Is Fair To Shareholders

The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Kite Pharma, Inc.

Biotech M&A: Who's Next After Gilead-Kite?

Biotech M&A: Who's Next After Gilead-Kite?

Prospects for acquisition activity in the sector are improving.

Cramer: Rebuilding After Hurricane Harvey Will Be Faster Than After Katrina

Cramer: Rebuilding After Hurricane Harvey Will Be Faster Than After Katrina

That would mean that there is the chance for a comeback here of some note.

Elliott Notches Win at Advisory Board, Monitors Progress with NRG - ICYMI

Elliott Notches Win at Advisory Board, Monitors Progress with NRG - ICYMI

Here's what you need to know now for Tuesday, August 29.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors Of An Investigation Concerning Whether The Sale Of Kite Pharma, Inc. To Gilead Sciences, Inc. Is Fair To Shareholders

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors Of An Investigation Concerning Whether The Sale Of Kite Pharma, Inc. To Gilead Sciences, Inc. Is Fair To Shareholders

The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Kite Pharma, Inc.

Juno Therapeutics Stock Climbs, Wedbush Sees Advantages from Gilead, Kite Deal

Juno Therapeutics Stock Climbs, Wedbush Sees Advantages from Gilead, Kite Deal

Juno Therapeutics stock was upgraded at Wedbush as Gilead's proposed deal for Kite Pharma raises awareness of Juno's treatments.

Markets Focus on Business: Cramer's 'Mad Money' Recap (Monday 8/28/17 )

Markets Focus on Business: Cramer's 'Mad Money' Recap (Monday 8/28/17 )

Jim Cramer says people care about natural disasters, but the markets are moved by data points, such as Apple's iPhone news.